StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)

Close on Nov 18, 2026Market cap $226.76MP/E –Yield –

Vanda Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Vanda Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $122.02M, up 21.9% year over year. For fiscal 2025 it was $109.27M, up 46.8% from the year before. Over ten years it grew 14.1% a year on average. The highest annual figure on record is $109.27M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$109.27M+46.8%
FY2024Dec 31, 2024$74.43M-3.1%
FY2023Dec 31, 2023$76.82M-10.4%
FY2022Dec 31, 2022$85.77M+13.8%
FY2021Dec 31, 2021$75.36M+35.6%
FY2020Dec 31, 2020$55.58M+14.2%
FY2019Dec 31, 2019$48.65M+11.6%
FY2018Dec 31, 2018$43.59M+13.1%
FY2017Dec 31, 2017$38.55M+32.2%
FY2016Dec 31, 2016$29.16M+0.0%
FY2015Dec 31, 2015$29.15M+51.6%
FY2014Dec 31, 2014$19.23M-32.5%
FY2013Dec 31, 2013$28.50M-37.7%
FY2012Dec 31, 2012$45.76M+57.8%
FY2011Dec 31, 2011$29.00M+135.0%
FY2010Dec 31, 2010$12.34M-11.1%
FY2009Dec 31, 2009$13.87M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$27.62M+22.4%
Q2 FY2026Jun 30, 2026$36.95M+68.0%
Q1 FY2026Mar 31, 2026$28.44M-20.4%
Q4 FY2025Dec 31, 2025$29.01M+46.2%
Q3 FY2025Sep 30, 2025$22.56M+34.5%
Q2 FY2025Jun 30, 2025$21.99M+32.0%
Q1 FY2025Mar 31, 2025$35.71M+68.8%
Q4 FY2024Dec 31, 2024$19.84M-18.5%
Q3 FY2024Sep 30, 2024$16.78M+1.1%
Q2 FY2024Jun 30, 2024$16.66M+0.1%
Q1 FY2024Mar 31, 2024$21.15M+10.0%
Q4 FY2023Dec 31, 2023$24.34M+31.9%
Q3 FY2023Sep 30, 2023$16.60M-33.2%
Q2 FY2023Jun 30, 2023$16.65M-22.5%
Q1 FY2023Mar 31, 2023$19.24M-8.3%
Q4 FY2022Dec 31, 2022$18.45M-4.5%
Q3 FY2022Sep 30, 2022$24.86M+26.5%
Q2 FY2022Jun 30, 2022$21.49M+6.1%
Q1 FY2022Mar 31, 2022$20.97M+30.0%
Q4 FY2021Dec 31, 2021$19.33M+30.2%
Q3 FY2021Sep 30, 2021$19.65M+59.8%
Q2 FY2021Jun 30, 2021$20.25M+56.9%
Q1 FY2021Mar 31, 2021$16.13M+3.9%
Q4 FY2020Dec 31, 2020$14.85M+13.6%
Q3 FY2020Sep 30, 2020$12.30M+8.4%
Q2 FY2020Jun 30, 2020$12.90M+17.8%
Q1 FY2020Mar 31, 2020$15.53M+16.9%
Q4 FY2019Dec 31, 2019$13.07M+1.2%
Q3 FY2019Sep 30, 2019$11.35M-0.4%
Q2 FY2019Jun 30, 2019$10.95M+11.0%
Q1 FY2019Mar 31, 2019$13.28M+41.0%
Q4 FY2018Dec 31, 2018$12.92M+27.3%
Q3 FY2018Sep 30, 2018$11.39M+11.9%
Q2 FY2018Jun 30, 2018$9.87M+29.0%
Q1 FY2018Mar 31, 2018$9.42M-10.9%
Q4 FY2017Dec 31, 2017$10.15M+33.4%
Q3 FY2017Sep 30, 2017$10.18M–
Q2 FY2017Jun 30, 2017$7.65M–
Q1 FY2017Mar 31, 2017$10.57M–
Q4 FY2016Dec 31, 2016$7.61M–

More Vanda Pharmaceuticals figures

See a number that looks wrong?